Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2013-11-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class
drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant
to standard chemotherapy or are otherwise not eligible for conventional chemotherapy.
Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects
within normal and malignant cells that affect cell growth and cell death.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania